By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -Novo Nordisk's shares fell nearly 5% on Friday after ...

Novo Nordisk fell more than 4% on Friday to their lowest level since Aug. 10 after the Danish drugmaker reported results from ...

Novo Nordisk's shares dropped nearly 5% after their experimental obesity pill, monlunabant, showed underwhelming Phase 2a trial results. The pill, acquired through a $1 billion deal with Inversago ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

NVO stock gains 4.2% after it presents efficacy data superior to Wegovy for its new oral pill, amycretin, in an early-stage ...

Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...

Stocks of LLY, VKTX and GPCR, which make oral pills for obesity, rose on Wednesday in response to Novo Nordisk's positive ...

Ozempic maker Novo Nordisk’s highly anticipated new obesity pill, Amycretin, shows the potential for much greater and faster ...

A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...

Shares in Roche dropped to a two-month low on Thursday after an experimental weight-loss pill that carries high market hopes ...

Roche Holding AG said side effects in a highly anticipated study of its experimental obesity pill were milder when it eased ...

Novo Nordisk said on Wednesday its highly anticipated experimental weight-loss pill amycretin was safe and tolerable for ...